文献速递眼底病与葡萄膜炎

HARBOR研究中新生血管性年龄相关性黄斑变性眼的光相干断层扫描生物标志物与玻璃体内雷珠单抗注射次数的关系

RELATIONSHIP BETWEEN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS AND NUMBER OF INTRAVITREAL RANIBIZUMAB INJECTIONS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE HARBOR STUDY.
PubMed 文献 · Retina · 2024-01-01

研究纳入HARBOR研究中236只新生血管性年龄相关性黄斑变性眼,接受雷珠单抗0.5 mg按需治疗,评估基线谱域光相干断层扫描特征与24个月内注射次数的相关性。结果显示0.5 mg按需组12个月平均注射8.07次、24个月平均14.25次,多因素线性回归分析中仅基线视网膜下液厚度较大与12和24个月更高的注射频率独立相关。

要点

  • 0.5 mg按需组12个月平均注射8.07次(中位数8,范围3-12)。
  • 0.5 mg按需组24个月平均注射14.25次(中位数14,范围3-24)。
  • 基线视网膜下液厚度较大与12和24个月更高注射频率独立相关。

核心结论

  • 基线视网膜下液厚度较大与新生血管性年龄相关性黄斑变性眼接受雷珠单抗按需治疗12和24个月更高的注射频率相关。
  • 这些发现可能对即将开始黄斑新生血管治疗患者的咨询有价值。

研究设计与样本

  • HARBOR研究中的236只新生血管性年龄相关性黄斑变性眼(236名受试者),接受雷珠单抗0.5 mg按需治疗。
  • 基线谱域光相干断层扫描图像由认证阅读中心分级师评估黄斑新生血管病灶及周围视网膜的特定形态学特征。
  • 分析基线光相干断层扫描特征和患者人口学资料与接下来2年注射次数的相关性。

主要发现

  • 0.5 mg按需组12个月平均注射次数为8.07次(中位数8,范围3-12)。
  • 0.5 mg按需组24个月平均注射次数为14.25次(中位数14,范围3-24)。
  • 经多因素线性回归分析,仅基线视网膜下液厚度较大这一基线参数与12和24个月更高的注射频率独立相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To correlate baseline spectral-domain optical coherence tomography characteristics with the number of as-needed intravitreal injections of ranibizumab over a 24-month follow-up period in eyes with neovascular age-related macular degeneration. METHODS: Two hundred thirty-six eyes of 236 subjects with neovascular age-related macular degeneration treated with ranibizumab 0.5 mg pro re nata in the HARBOR study were enrolled. Baseline spectral-domain optical coherence tomography images were evaluated by certified reading center graders for specific morphologic features of the macular neovascularization lesion and surrounding retina. Baseline optical coherence tomography features and patient demographics correlated with the number of injections over the next 2 years. RESULTS: The mean number of injections in the 0.5 mg pro re nata group was 8.07 (median 8, 3-12) after 12 months and 14.25 (median 14, 3-24) after 24 months of treatment. After multivariate, linear, regression analysis, the only baseline parameter that was independently associated with a higher injection frequency at both 12 and 24 months was a greater baseline subretinal fluid thickness. CONCLUSION: A greater subretinal fluid thickness at baseline was associated with a higher frequency of pro re nata injections over 12 and 24 months in eyes treated with ranibizumab for neovascular age-related macular degeneration. These findings may be of value in counseling patients who are about to initiate therapy for macular neovascularization.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Tong N, Fan W, Su L, et al. RELATIONSHIP BETWEEN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS AND NUMBER OF INTRAVITREAL RANIBIZUMAB INJECTIONS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE HARBOR STUDY. Retina. 2024. PMID: 39287532. doi:10.1097/IAE.0000000000004171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。